This Week In Virology With Vincent Racaniello

In his weekly clinical update, Dr. Griffin discusses the use of monoclonal antibody therapy to prevent RSV hospitalization of infants and use of GSK’s RSV vaccine Arexy to prevent severe disease following RSV infection in adults between 50-59 years before he reviews recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if how the influenza vaccine is manufactured can reprogram the antibody response, cardiovascular consequences of influenza infection, mortality of chikungunya virus infection, if an alternative vaccination schedule impacts the anti-SARS-CoV-2 immune response, dispels the myth that increased mortality correlated with the first vaccine dose, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how manage long COVID including prevent burnout and compassion fatigue of caring for long COVID patients, whether the